REG - Allergy Therapeutics - Exercise of Options and Total Voting Rights

Allergy TherapeuticsAnnouncement

09/11/2023 11:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231109:nRSI9644Sa&default-theme=true

RNS Number : 9644S  Allergy Therapeutics PLC  09 November 2023

 

Allergy Therapeutics plc

("Allergy Therapeutics", the "Group" or "Company")

 

Exercise of Options and Total Voting Rights

Rule 2.9 announcement

 

9 November 2023 Allergy Therapeutics plc (AIM: AGY) announces that the
Company has allotted and issued a total of 5,229,074 new ordinary shares of
£0.001 each in the Company ("New Ordinary Shares") following the exercise of
5,229,074 options by certain current and former employees. Of these, 5,197,965
options were exercised as a result of the recent equity financing that
constituted a change of control for the purposes of the Company's Long Term
Share Incentive Plan and 31,109 options were exercised in connection with
proposals made to the holders of those options pursuant to Rule 15 of the
Code, as described in the offer document published on 19 October 2023.

As a result of the exercise of options, the New Ordinary Shares have been
admitted to trading on AIM pursuant to the Company's existing block admission
facility. The New Ordinary Shares rank pari passu with the existing shares
of the Company.

In accordance with Rule 2.9 of the City Code on Takeovers and Mergers the
Company confirms that, on 9 November 2023 (the date of this announcement), it
has 4,758,946,227 ordinary shares of £0.001 each in issue. This figure may
be used by shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or a change
to their interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.

The International Securities Identification Number for Allergy Therapeutics
Shares is GB00B02LCQ05.

 

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Panmure Gordon (Rule 3 Adviser, Nominated Adviser and Broker)

Emma Earl, Mark Rogers, Freddy Crossley, Corporate Finance

Rupert Dearden, Corporate Broking

+44 (0)20 7886 2500

 

ICR Consilium

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third-party
products from its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad pipeline of
products in clinical development includes vaccines for grass, tree, house dust
mite and peanut. For more information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRFSLFSUEDSELF